MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/07853890.2026.2720965

Медицинская библиотека · Annals of medicine · 2026

Clinical and inflammatory determinants of successful abrocitinib dose reduction in atopic dermatitis: a real-world cohort study with implications for treatment optimization.

Wang Yu, Qin Haihong, Gao Yuwen, Li Zheng, Wu Yuemeng, Yin Huibin, Wang Shangshang, Yao Xu, Wu Hao, Gu Chaoying

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Abrocitinib, a selective Janus kinase 1 inhibitor, is an effective therapy for moderate-to-severe atopic dermatitis (AD). However, evidence guiding dose reduction during long-term maintenance in real-world practice remains limited, and determinants of successful dose tapering are unclear.

OBJECTIVE

To evaluate the feasibility of abrocitinib dose reduction and identify clinical and immunological features associated with tapering.

METHODS

In this prospective real-world study, 66 adults with moderate-to-severe AD received standard-dose abrocitinib for 12 weeks, followed by individualized dose adjustment based on disease control. Clinical outcomes and serum cytokine profiles were assessed longitudinally to characterize treatment responses and immunological correlates of dose reduction.

RESULTS

Baseline disease severity was comparable between groups defined by dose-adjustment outcomes. Patients requiring dose maintenance or escalation had a longer disease duration and higher prevalence of atopic comorbidities and family history, whereas those achieving dose reduction tended to be older. By Week 12, the dose-reduction group achieved significantly lower Eczema Area and Severity Index scores, pruritus numerical rating scale scores and eosinophil counts. These differences persisted during long-term follow-up despite dose reduction. Cytokine analyses demonstrated significantly lower IL-13 levels at Week 12, with consistent trends towards reduced inflammatory activity during maintenance therapy.

CONCLUSIONS

Successful abrocitinib dose reduction appears to occur in a clinically distinct subgroup characterized by shorter disease duration, lower atopic burden and deeper early treatment responses. Patients achieving dose tapering exhibited a more quiescent inflammatory profile. These findings support an individualized treatment-optimization strategy aimed at maintaining long-term disease control with the minimal effective dose.

Для цитирования: Wang Yu, Qin Haihong, Gao Yuwen, Li Zheng, Wu Yuemeng, Yin Huibin, Wang Shangshang, Yao Xu, Wu Hao, Gu Chaoying. Clinical and inflammatory determinants of successful abrocitinib dose reduction in atopic dermatitis: a real-world cohort study with implications for treatment optimization.. Annals of medicine. 2026. DOI: 10.1080/07853890.2026.2720965.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.